MaxCyte Inc (NASDAQ: MXCT) kicked off on Tuesday, down -6.06% from the previous trading day, before settling in for the closing price of $1.65. Over the past 52 weeks, MXCT has traded in a range of $1.26-$5.20.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -11.37%. While this was happening, its average annual earnings per share was recorded -9.62%. With a float of $97.60 million, this company’s outstanding shares have now reached $106.59 million.
MaxCyte Inc (MXCT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of MaxCyte Inc is 8.45%, while institutional ownership is 68.24%. The most recent insider transaction that took place on Jun 25 ’25, was worth 22,378. In this transaction Director of this company sold 10,684 shares at a rate of $2.09, taking the stock ownership to the 39,893 shares. Before that another transaction happened on Aug 13 ’25, when Company’s CHIEF FINANCIAL OFFICER bought 50,000 for $1.29, making the entire transaction worth $64,500. This insider now owns 161,811 shares in total.
MaxCyte Inc (MXCT) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.11 earnings per share (EPS), higher than consensus estimate (set at -0.12) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.11% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Take a look at MaxCyte Inc’s (MXCT) current performance indicators. Last quarter, stock had a quick ratio of 11.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Compared to the last year’s volume of 0.79 million, its volume of 0.81 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 55.47%.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 25.44%, which indicates a significant decrease from 27.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1174 in the past 14 days, which was higher than the 0.1089 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5494, while its 200-day Moving Average is $2.7161. Nevertheless, the first resistance level for the watch stands at $1.6407 in the near term. At $1.7313, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7767. If the price goes on to break the first support level at $1.5047, it is likely to go to the next support level at $1.4593. Should the price break the second support level, the third support level stands at $1.3687.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
The company with the Market Capitalisation of 165.24 million has total of 106,607K Shares Outstanding. Its annual sales at the moment are 38,630 K in contrast with the sum of -41,060 K annual income. Company’s last quarter sales were recorded 8,510 K and last quarter income was -12,360 K.
